866-997-4948(US-Canada Toll Free)

Anticancer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Published By :

Transparency Market Research

Published Date : Jan 2018

Category :

Pharmaceutical

No. of Pages : 226 Pages

Global Anticancer drugs Market: Scope and Research Methodology

This report on the global anticancer drugs market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global anticancer drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global anticancer drugs market.

Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year. Market size estimations involved in-depth study of features of different type of drugs, therapies and cancer types. Additionally, market related factors such as rise in preference of targeted therapies, high prevalence rate of cancer, rise in per capita healthcare expenditure etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Anticancer drugs Market: Segmentation

Cancer is caused due to abnormal growth of the cells. Anticancer drugs are also known as antineoplastic drugs. These drugs prevents and inhibits the growth of cancer cells.

Based on drug types, global anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, and hormonal drugs. The targeted drugs segment is further segmented into monoclonal antibodies, tyrosine kinase inhibitors and others. The segment is anticipated to hold a significant share of the global market. The targeted drugs have a significant demand and is expected to continue dominating the global market throughout the forecast period.

Based on therapy type, global anticancer drugs market is segmented into chemotherapy, targeted therapy, immunotherapy and others. Targeted therapy held the highest share of the market and is anticipated to dominate the market during the forecast period. Side effects of chemotherapy and specificity of the targeted drug are the factors driving the growth of global market.

Based on cancer types, the global anticancer drugs market is segmented into lung cancer, breast cancer, leukemia, colorectal cancer and others. The lung cancer segment is expected to expand at the fast rate due to high prevalence of the disease worldwide.

Anticancer drugs Market: Geographical and Competitive Dynamics

Geographically, the global anticancer drugs market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In addition, the regions have been further segmented by major countries from each region.

The report also profiles major players in the anticancer drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.

The global anticancer drugs market has been segmented as follows:

Global Anticancer drugs Market, by Drug Type

  • Cytotoxic Drugs
    • Alkylating Agents
    • Antimetabolites
    • Others
  • Targeted Drugs
    • Monoclonal Antibodies
    • Tyrosine Kinase Inhibitors
    • Others
  • Hormonal Drugs

Global Anticancer drugs Market, by Therapy Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others

Global Anticancer drugs Market, by Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Leukemia
  • Colorectal Cancer
  • Others

Global Anticancer Drugs Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & NZ
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of MEA

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Anticancer Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.3.4. Trends
4.4. Global Anticancer Drugs Market Analysis and Forecasts, 2015-2025
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
4.6. Value Chain Analysis
4.7. Market Outlook
4.8. Pipeline Analysis
4.9. Disease Overview
4.10. Evolution of Cancer Therapies

5. Global Anticancer Drugs Market Analysis and Forecasts, By Drug Type 
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast By Drug Type , 2015-2025
5.3.1. Cytotoxic Drugs
5.3.1.1. Alkylating Agents
5.3.1.2. Antimetabolites
5.3.1.3. Others
5.3.2. Targeted Drugs
5.3.2.1. Monoclonal Antibodies
5.3.2.2. Tyrosine Kinase Inhibitors
5.3.2.3. Others
5.3.3. Hormonal Drugs
5.4. Market Attractiveness By Drug Type 

6. Global Anticancer Drugs Market Analysis and Forecasts, By Therapy Type 
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Therapy Type , 2015-2025
6.3.1. Chemotherapy
6.3.2. Targeted Therapy
6.3.3. Immunotherapy
6.3.4. Others
6.4. Market Attractiveness By Therapy Type 

7. Global Anticancer Drugs Market Analysis and Forecasts, By Cancer Type 
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Cancer Type , 2015-2025
7.3.1. Lung Cancer
7.3.2. Breast Cancer
7.3.3. Leukemia
7.3.4. Colorectal Cancer
7.3.5. Others
7.4. Market Attractiveness By Cancer Type 

8. Global Anticancer Drugs Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America 
8.2.2. Europe 
8.2.3. Asia Pacific 
8.2.4. Latin America 
8.2.5. Middle East & Africa 
8.3. Market Attractiveness By Region

9. North America Anticancer Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Key Trends
9.2. Market Value Forecast By Drug Type , 2015-2025
9.2.1. Cytotoxic Drugs
9.2.1.1. Alkylating Agents
9.2.1.2. Antimetabolites
9.2.1.3. Others
9.2.2. Targeted Drugs
9.2.2.1. Monoclonal Antibodies
9.2.2.2. Tyrosine Kinase Inhibitors
9.2.2.3. Others
9.2.3. Hormonal Drugs
9.3. Market Value Forecast By Therapy Type , 2015-2025
9.3.1. Chemotherapy
9.3.2. Targeted Therapy
9.3.3. Immunotherapy
9.3.4. Others
9.4. Market Value Forecast By Cancer Type , 2015-2025
9.4.1. Lung Cancer
9.4.2. Breast Cancer
9.4.3. Leukemia
9.4.4. Colorectal Cancer
9.4.5. Others
9.5. Market Value Forecast By Country, 2015-2025
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis 
9.6.1. By Drug Type 
9.6.2. By Therapy Type 
9.6.3. By Cancer Type 
9.6.4. By Country

10. Europe Anticancer Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Key Trends
10.2. Market Value Forecast By Drug Type , 2015-2025
10.2.1. Cytotoxic Drugs
10.2.1.1. Alkylating Agents
10.2.1.2. Antimetabolites
10.2.1.3. Others
10.2.2. Targeted Drugs
10.2.2.1. Monoclonal Antibodies
10.2.2.2. Tyrosine Kinase Inhibitors
10.2.2.3. Others
10.2.3. Hormonal Drugs
10.3. Market Value Forecast By Therapy Type , 2015-2025
10.3.1. Chemotherapy
10.3.2. Targeted Therapy
10.3.3. Immunotherapy
10.3.4. Others
10.4. Market Value Forecast By Cancer Type , 2015-2025
10.4.1. Lung Cancer
10.4.2. Breast Cancer
10.4.3. Leukemia
10.4.4. Colorectal Cancer
10.4.5. Others
10.5. Market Value Forecast By Country / Sub-region, 2015-2025
10.5.1. U.K. 
10.5.2. Germany
10.5.3. France
10.5.4. Italy 
10.5.5. Spain 
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis 
10.6.1. By Drug Type 
10.6.2. By Therapy Type 
10.6.3. By Cancer Type 
10.6.4. By Country / Sub-region

11. Asia Pacific Anticancer Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Key Trends
11.2. Market Value Forecast By Drug Type , 2015-2025
11.2.1. Cytotoxic Drugs
11.2.1.1. Alkylating Agents
11.2.1.2. Antimetabolites
11.2.1.3. Others
11.2.2. Targeted Drugs
11.2.2.1. Monoclonal Antibodies
11.2.2.2. Tyrosine Kinase Inhibitors
11.2.2.3. Others
11.2.3. Hormonal Drugs
11.3. Market Value Forecast By Therapy Type , 2015-2025
11.3.1. Chemotherapy
11.3.2. Targeted Therapy
11.3.3. Immunotherapy
11.3.4. Others
11.4. Market Value Forecast By Cancer Type , 2015-2025
11.4.1. Lung Cancer
11.4.2. Breast Cancer
11.4.3. Leukemia
11.4.4. Colorectal Cancer
11.4.5. Others
11.5. Market Value Forecast By Country / Sub-region, 2015-2025
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis 
11.6.1. By Drug Type 
11.6.2. By Therapy Type 
11.6.3. By Cancer Type 
11.6.4. By Country / Sub-region

12. Latin America Anticancer Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Key Trends
12.2. Market Value Forecast By Drug Type , 2015-2025
12.2.1. Cytotoxic Drugs
12.2.1.1. Alkylating Agents
12.2.1.2. Antimetabolites
12.2.1.3. Others
12.2.2. Targeted Drugs
12.2.2.1. Monoclonal Antibodies
12.2.2.2. Tyrosine Kinase Inhibitors
12.2.2.3. Others
12.2.3. Hormonal Drugs
12.3. Market Value Forecast By Therapy Type , 2015-2025
12.3.1. Chemotherapy
12.3.2. Targeted Therapy
12.3.3. Immunotherapy
12.3.4. Others
12.4. Market Value Forecast By Cancer Type , 2015-2025
12.4.1. Lung Cancer
12.4.2. Breast Cancer
12.4.3. Leukemia
12.4.4. Colorectal Cancer
12.4.5. Others
12.5. Market Value Forecast By Country / Sub-region, 2015-2025
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis 
12.6.1. By Drug Type 
12.6.2. By Therapy Type 
12.6.3. By Cancer Type 
12.6.4. By Country / Sub-region

13. Middle East & Africa Anticancer Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Key Trends
13.2. Market Value Forecast By Drug Type , 2015-2025
13.2.1. Cytotoxic Drugs
13.2.1.1. Alkylating Agents
13.2.1.2. Antimetabolites
13.2.1.3. Others
13.2.2. Targeted Drugs
13.2.2.1. Monoclonal Antibodies
13.2.2.2. Tyrosine Kinase Inhibitors
13.2.2.3. Others
13.2.3. Hormonal Drugs
13.3. Market Value Forecast By Therapy Type , 2015-2025
13.3.1. Chemotherapy
13.3.2. Targeted Therapy
13.3.3. Immunotherapy
13.3.4. Others
13.4. Market Value Forecast By Cancer Type , 2015-2025
13.4.1. Lung Cancer
13.4.2. Breast Cancer
13.4.3. Leukemia
13.4.4. Colorectal Cancer
13.4.5. Others
13.5. Market Value Forecast By Country / Sub-region, 2015-2025
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of MEA
13.6. Market Attractiveness Analysis 
13.6.1. By Drug Type 
13.6.2. By Therapy Type 
13.6.3. By Cancer Type 
13.6.4. By Country / Sub-region

14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2016)
14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.3.1. F. Hoffmann-La Roche Ltd
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Eli Lilly and Company
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Pfizer Inc
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Bayer AG
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. AstraZeneca
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.7. Takeda Pharmaceutical Company Limited
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Merck & Co., Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. CELGENE CORPORATION
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Amgen Inc
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview

List of Table

Table 01: Pipeline Analysis, by Phase III
Table 02: Pipeline Analysis, By Phase II and Phase I
Table 03: Pipeline Analysis, By Preclinical Trial (1/2)
Table 04: Pipeline Analysis, By Preclinical Trial (2/2)
Table 05: Global Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 06: Global Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 2015–2025
Table 07: Global Anticancer Drugs Market Value (US$ Mn) Forecast, by Targeted Drugs, 2015–2025
Table 08: Global Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type, 2015–2025
Table 09: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Therapy Type, 2015–2025
Table 10: Global Anticancer Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 11: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 12: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 
Table 13: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type – Targeted Drugs , 2015–2025
Table 14: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type,
Table 15: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 16: North America Anticancer Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 17: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 18: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 
Table 19: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type – Targeted Drugs , 2015–2025
Table 20: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type,
Table 21: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 22: Europe Anticancer Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 23: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 24: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 
Table 25: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type – Targeted Drugs , 2015–2025
Table 26: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type,
Table 27: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 28: Asia Pacific Anticancer Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 29: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 30: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 
Table 31: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type – Targeted Drugs , 2015–2025
Table 32: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type,
Table 33: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 34: Latin America Anticancer Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 35: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2015–2025
Table 36: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Cytotoxic Drugs, 
Table 37: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Drug Type – Targeted Drugs , 2015–2025
Table 38: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Therapy Type,
Table 39: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Cancer Type, 2015–2025
Table 40: Middle East & Africa Anticancer Drugs Market Value (US$ Mn) Forecast, by Country, 2015–2025

List of Chart

Figure 01: Global Anticancer Drugs Market, by Drug Type, Market Size (US$ Mn), 2016 (A)
Figure 02:  Global Anticancer Drugs Market Revenue (%), by Cancer Therapy, 2016 (A)
Figure 03:  Global Anticancer Drugs Market Revenue (%), by Region, 2016 (A)
Figure 04: Opportunity Map, By Drug Type 2016
Figure 05: Opportunity Map, By Therapy type and Cancer Type 2016
Figure 06: Global Anticancer Drugs Market - Key Industry Developments
Figure 07: Global Anticancer Drugs Market Size (US$ Mn) Forecast, 2015–2025
Figure 08: Porter’s Five Forces Analysis
Figure 09: Global Anticancer Drugs Market - Value Chain Analysis
Figure 10: Market Value Share, by Drug Type (2016)
Figure 11: Market Value Share, by Therapy Type (2016)
Figure 12: Market Value Share, by Cancer Types (2016)
Figure 13: Global Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 14: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cytotoxic Drugs, 2015–2025
Figure 15: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Drugs, 2015–2025
Figure 16: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hormonal Drugs, 2015–2025
Figure 17: Global Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 18: Global Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 19: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemotherapy, 2015–2025
Figure 20: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Therapy, 2015–2025
Figure 21: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunotherapy, 2015–2025
Figure 22: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunotherapy, 2015–2025
Figure 23: Global Anticancer Drugs Market Attractiveness Analysis, by Therapy Type 
Figure 24: Global Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 25: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Lung Cancer, 2015–2025
Figure 26: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Breast Cancer, 2015–2025
Figure 27: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Leukemia, 2015–2025
Figure 28: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Colorectal Cancer, 2015–2025
Figure 29: Global Anticancer Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 30: Global Anticancer Drugs Market Attractiveness Analysis, by Cancer Type, 2017–2025
Figure 31: Global Scenario of Anticancer Drugs Market 
Figure 32: Global Anticancer Drugs Market Value Share Analysis, by Region, 2016 and 2025
Figure 33: Global Anticancer Drugs Market Attractiveness Analysis, by Region
Figure 34: North America Anticancer Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 35: North America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 36: North America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 37: North America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 38: North America Anticancer Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 39: North America Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 40: North America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type
Figure 41: North America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type 
Figure 42: North America Market Attractiveness Analysis, by Country
Figure 43: Europe Anticancer Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 44: Europe Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 45: Europe Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 46: Europe Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 47: Europe Anticancer Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 48: Europe Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 49: Europe Anticancer Drugs Market Attractiveness Analysis, by Therapy Type
Figure 50: Europe Anticancer Drugs Market Attractiveness Analysis, by Cancer Type 
Figure 51: Europe Market Attractiveness Analysis, by Country
Figure 52: Asia Pacific Anticancer Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 53: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 54: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 55: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 56: Asia Pacific Anticancer Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 57: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 58: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Therapy Type
Figure 59: Asia Pacific Anticancer Drugs Market Attractiveness Analysis, by Cancer Type 
Figure 60:Asia Pacific Market Attractiveness Analysis, by Country
Figure 61: Latin America Anticancer Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 62: Latin America Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 63: Latin America Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 64: Latin America Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 65: Latin America Anticancer Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 66: Latin America Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 67: Latin America Anticancer Drugs Market Attractiveness Analysis, by Therapy Type
Figure 68: Latin America Anticancer Drugs Market Attractiveness Analysis, by Cancer Type 
Figure 69: Latin America Market Attractiveness Analysis, by Country
Figure 70: Middle East & Africa Anticancer Drugs Market Size (US$ Mn) Forecast, 2017–2025
Figure 71: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Drug Type, 2016 and 2025
Figure 72: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Therapy Type, 2016 and 2025
Figure 73: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Cancer Type, 2016 and 2025
Figure 74: Middle East & Africa Anticancer Drugs Market Value Share Analysis, by Country, 2016 and 2025
Figure 75: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Drug Type
Figure 76: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Therapy Type
Figure 77: Middle East & Africa Anticancer Drugs Market Attractiveness Analysis, by Cancer Type 
Figure 78: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 79: Global  Anticancer Drugs Market Share Analysis, by Company (2016)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *